Suppr超能文献

[他唑巴坦/哌拉西林和他唑巴坦对大鼠的六个月腹腔内重复给药毒性研究]

[A six-month intraperitoneal repeated dose toxicity study of tazobactam/piperacillin and tazobactam in rats].

作者信息

Hayashi T, Yada H, Auletta C S, Daly I W, Knezevich A L, Cockrell B Y

机构信息

Drug Safety Laboratory, Taiho Pharmaceutical Co., Ltd., Tokushima, Japan.

出版信息

J Toxicol Sci. 1994 Oct;19 Suppl 2:155-76. doi: 10.2131/jts.19.supplementii_155.

Abstract

Tazobactam (TAZ) is a newly developed beta-lactamase inhibitor. Tazobactam/Piperacillin (TAZ/PIPC) is a formulation consisting of TAZ and PIPC in a ratio of 1:4. A six-month intraperitoneal repeated dose toxicity study of TAZ/PIPC and TAZ including a one-month recovery period were carried out using male and female rats. The doses were 200, 400 and 800 mg/kg/day for TAZ/PIPC, and 40, 80 and 160 mg/kg/day for TAZ. The results were as follows. 1. No test article-related deaths occurred during the study period. No effect on clinical finding of survival rats was evident. 2. There was no dose-related increases of food consumption in both the males and females given TAZ/PIPC and PIPC. Slight reductions in body weight gain occurred in males given 800 mg/kg/day of TAZ/PIPC. 3. Decreases in erythrocyte, hemoglobin and hematocrit, and increases in reticulocytes were seen only at study termination in the group given 800 mg/kg/day of TAZ/PIPC. Increases in reticulocytes were seen only at study termination in the females given 80 or 160 mg/kg/day of TAZ. 4. A decrease in triglyceride levels was observed in the males given 800 mg/kg/day of TAZ/PIPC or 160 mg/kg/day of TAZ. 5. The ophthalmoscopic examination or urinalysis show no test article-related changes. 6. Enlarged ceca in all groups of animals given TAZ/PIPC and in the females given 160 mg/kg/day of TAZ were observed. 7. An increase of relative organ weight in liver was noted in the males and females given 800 mg/kg/day of TAZ/PIPC, in the males given 80 or 160 mg/kg/day of TAZ and in the females given 160 mg/kg/day of TAZ. 8. In the hepatocytes, accumulation of PAS-positive materials which was identified histochemically and ultrastructurally as glycogen, was present in the males given 800 mg/kg/day of TAZ/PIPC and in the males given 80 or 160 mg/kg/day of TAZ. 9. After a one-month recovery period, the changes of liver had generally disappeared, suggesting that they were reversible. 10. From the histopathological changes of liver, the no-toxic dose level in both the males and females was 400 mg/kg/day and 40 mg/kg/day for TAZ/PIPC and TAZ, respectively.

摘要

他唑巴坦(TAZ)是一种新开发的β-内酰胺酶抑制剂。他唑巴坦/哌拉西林(TAZ/PIPC)是一种由TAZ和PIPC按1:4比例组成的制剂。使用雄性和雌性大鼠进行了TAZ/PIPC和TAZ的为期六个月的腹腔重复给药毒性研究,包括一个月的恢复期。TAZ/PIPC的剂量为200、400和800毫克/千克/天,TAZ的剂量为40、80和160毫克/千克/天。结果如下:1. 在研究期间未发生与受试物相关的死亡。对存活大鼠的临床观察未发现明显影响。2. 给予TAZ/PIPC和PIPC的雄性和雌性大鼠的食物摄入量均未出现与剂量相关的增加。给予800毫克/千克/天TAZ/PIPC的雄性大鼠体重增加略有减少。3. 仅在给予800毫克/千克/天TAZ/PIPC的组中,在研究结束时观察到红细胞、血红蛋白和血细胞比容降低,网织红细胞增加。仅在给予80或160毫克/千克/天TAZ的雌性大鼠研究结束时观察到网织红细胞增加。4. 给予800毫克/千克/天TAZ/PIPC或160毫克/千克/天TAZ的雄性大鼠甘油三酯水平降低。5. 眼底检查或尿液分析未显示与受试物相关的变化。6. 在给予TAZ/PIPC的所有动物组以及给予160毫克/千克/天TAZ的雌性大鼠中观察到盲肠增大。7. 给予800毫克/千克/天TAZ/PIPC的雄性和雌性大鼠、给予80或160毫克/千克/天TAZ的雄性大鼠以及给予160毫克/千克/天TAZ的雌性大鼠肝脏相对器官重量增加。8. 在给予800毫克/千克/天TAZ/PIPC的雄性大鼠以及给予80或160毫克/千克/天TAZ的雄性大鼠的肝细胞中,经组织化学和超微结构鉴定为糖原的PAS阳性物质蓄积。9. 经过一个月的恢复期,肝脏变化通常消失,表明它们是可逆的。10. 从肝脏的组织病理学变化来看,TAZ/PIPC和TAZ在雄性和雌性中的无毒剂量水平分别为400毫克/千克/天和40毫克/千克/天。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验